Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Moderna, Inc. (MRNA : NSDQ)
 
 • Company Description   
Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.

Number of Employees: 5,800

 
 • Price / Volume Information   
Yesterday's Closing Price: $46.60 Daily Weekly Monthly
20 Day Moving Average: 12,356,461 shares
Shares Outstanding: 390.73 (millions)
Market Capitalization: $18,208.19 (millions)
Beta: 1.32
52 Week High: $55.20
52 Week Low: $22.28
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.44% -6.52%
12 Week 86.32% 84.46%
Year To Date 58.02% 57.20%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
325 BINNEY STREET
-
CAMBRIDGE,MA 02142
USA		 ph: 617-714-6500
fax: -		 ir@modernatx.com http://www.modernatx.com
 
 • General Corporate Information   
Officers
Stephane Bancel - Chief Executive Officer
Noubar B. Afeyan - Chairman
James M. Mock - Chief Financial Officer
Sandra Horning - Director
Abbas Hussain - Director

Peer Information
Moderna, Inc. (CORR.)
Moderna, Inc. (RSPI)
Moderna, Inc. (CGXP)
Moderna, Inc. (BGEN)
Moderna, Inc. (GTBP)
Moderna, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 60770K107
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/25
Next Expected EPS Date: 05/07/26
Share - Related Items
Shares Outstanding: 390.73
Most Recent Split Date: (:1)
Beta: 1.32
Market Capitalization: $18,208.19 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-2.04 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-6.67 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 17.26% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/07/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.11
Price/Cash Flow: -
Price / Sales: 9.37
EPS Growth
vs. Year Ago Period: 15.60%
vs. Previous Quarter: -313.73%
Sales Growth
vs. Year Ago Period: -29.81%
vs. Previous Quarter: -33.27%
ROE
12/31/25 - -30.15
09/30/25 - -29.81
06/30/25 - -25.96
ROA
12/31/25 - -22.95
09/30/25 - -23.20
06/30/25 - -20.09
Current Ratio
12/31/25 - 3.29
09/30/25 - 3.92
06/30/25 - 3.93
Quick Ratio
12/31/25 - 3.22
09/30/25 - 3.73
06/30/25 - 3.77
Operating Margin
12/31/25 - -145.16
09/30/25 - -132.53
06/30/25 - -89.18
Net Margin
12/31/25 - -145.16
09/30/25 - -139.61
06/30/25 - -94.31
Pre-Tax Margin
12/31/25 - -142.39
09/30/25 - -141.26
06/30/25 - -95.68
Book Value
12/31/25 - 22.14
09/30/25 - 23.89
06/30/25 - 24.16
Inventory Turnover
12/31/25 - 4.07
09/30/25 - 5.65
06/30/25 - 6.52
Debt-to-Equity
12/31/25 - 0.07
09/30/25 - 0.00
06/30/25 - 0.00
Debt-to-Capital
12/31/25 - 6.59
09/30/25 - 0.28
06/30/25 - 0.34
 

Powered by Zacks Investment Research ©